Neogen Raises Full-Year Guidance on Strategic Transformation Progress and Sequential Improvement
NEOG has more than doubled off its 52-week low of $3.87.
Summary
Neogen reported mixed Q2 results but raised its full-year fiscal 2026 revenue and Adjusted EBITDA guidance, citing strategic transformation progress and sequential operational improvements.
Key Events · Earnings and Guidance · NEOG
-
Q2 Fiscal 2026 Results
Reported revenue of $224.7 million, a 2.8% decrease year-over-year, but core revenue increased by 2.9%. Net loss was $15.9 million, while Adjusted Net Income was $22.6 million.
-
Raised Full-Year Guidance
Increased fiscal year 2026 revenue outlook to $845 million - $855 million and Adjusted EBITDA to approximately $175 million, indicating improved future expectations.
-
Strategic Transformation Progress
Highlighted significant sequential improvement in core revenue growth and profitability, with the Petrifilm manufacturing transition on track and key senior commercial leaders hired.
Analysis · NEOG · Life Sciences
Neogen Corporation reported mixed second-quarter fiscal 2026 results, with a slight year-over-year revenue decrease but a positive core revenue growth. Despite a decline in adjusted net income and adjusted EBITDA compared to the prior year, the company demonstrated significant sequential improvement in core revenue growth and profitability. Management highlighted progress in its strategic transformation, including the integration of Petrifilm and optimization of manufacturing, alongside strengthening its leadership team. The most impactful aspect is the upward revision of its full-year fiscal 2026 revenue and Adjusted EBITDA guidance, signaling increased confidence in future performance and operational execution.
At the time of this filing, NEOG was trading at $8.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $3.87 to $13.41. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.